Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DR76TW
|
|||
| Drug Name |
LY3437943
|
|||
| Synonyms |
retatrutide
Click to Show/Hide
|
|||
| Drug Type |
Peptide
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66] | Phase 2 | [1] | |
| Type 2 diabetes [ICD-11: 5A11; ICD-10: E08-E13] | Phase 2 | [2] | ||
| Company |
Lilly Indianapolis, IN
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Gastric inhibitory polypeptide receptor (GIPR) | Target Info | Agonist | [3] |
| Glucagon receptor (GCGR) | Target Info | Agonist | [3] | |
| Glucagon-like peptide 1 receptor (GLP1R) | Target Info | Agonist | [3] | |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Insulin secretion | ||||
| Glucagon signaling pathway | ||||
| Reactome | Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | |||
| G alpha (s) signalling events | ||||
| Glucagon-type ligand receptors | ||||
| Glucagon signaling in metabolic regulation | ||||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04881760) A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04867785) A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes. U.S.National Institutes of Health. | |||
| REF 3 | LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022 Sep 6;34(9):1234-1247.e9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.